Viyash Scientific growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+120.5%+13.3%−3.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+303.3%+163.4%+413.7%
+339.4%+75,766.7%+99.7%
+596.4%+208.9%+75.7%
+364.8%+161.1%+70.5%
+188.9%+4.0%+0.7%
+304.3%+8.1%−4.8%
+287.4%+172.5%+82.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VIYASH₹224.55

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹9,809 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-3.6+13.3+120.5—
EBITDA Growth—+413.7+163.4+303.3—
EBIT Growth—+99.7+75,766.7+339.4—
Net Income Growth—+75.7+208.9+596.4—
EPS Growth—+70.5+161.1+364.8—
Total Assets Growth—+0.7+4.0+188.9—
Total Equity Growth—-4.8+8.1+304.3—
Cash from Operations Growth—+82.0+172.5+287.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.